Press Releases

Aug 25, 2021

PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

Aug 23, 2021

PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Aug 19, 2021

PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aug 16, 2021

PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus

Aug 12, 2021

PharmaCyte Biotech Announces Closing of $15-Million Public Offering

Aug 9, 2021

PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering

Aug 2, 2021

PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering

Jul 14, 2021

PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq

Jul 12, 2021

PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank

Jul 9, 2021

PharmaCyte Biotech Announces Reverse Stock Split